Table 3.

Toxicity risks of adjuvant polychemotherapy in older cancer patients.

Trial Name	Regime	Age Years: % Population	Toxicity in the Elderly
US Oncology 9735	TC vs. AC	≥65: 16%	TC: 2-fold risk of febrile neutropenia AC: 2-fold risk of anemia
IBCSG	Tam +/− CMF	≥65: 25%	CMF higher risk for Gr 3 toxicity of any type; mostly hematological and mucosal
CALGB 8541 CALGB 9344 CALGB 9741	FAC AC +/− paclitaxel AC + P standard vs. dense dose	≥65: 7% ≥70: 3%	Higher hematological toxicities, more treatment cessations

TC: Docetaxel and cyclophosphamide; AC; doxorubicin and cyclophosphamide; Tam: Tamoxifen; CMF: Cyclophosphamide, methotrexate and fluorouracil; +/−: With or without; >: Equal or greater than; Gr: Grade.